InspireMD Inc (NSPR)

Currency in USD
1.280
-0.040(-3.03%)
Closed·
1.340+0.060(+4.69%)
·
Unusual trading volume
Trading near 52-week Low
NSPR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.2501.350
52 wk Range
1.2502.932
Key Statistics
Prev. Close
1.28
Open
1.33
Day's Range
1.25-1.35
52 wk Range
1.25-2.932
Volume
92.96K
Average Volume (3m)
39.28K
1-Year Change
-49.0347%
Book Value / Share
1.3
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NSPR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
5.000
Upside
+290.62%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

InspireMD Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.

InspireMD Inc Earnings Call Summary for Q4/2025

  • InspireMD Q4 2025 EPS of -$0.14 beat forecast of -$0.19 by 26%; revenue of $3.15M exceeded estimates by 36%, driving 12.85% premarket stock surge.
  • Revenue grew 62% YoY to $3.1M, driven by CGuard Prime's U.S. launch post-FDA approval; gross margin expanded to 37.5% on favorable revenue mix.
  • U.S. market revenue reached $866K with 74% sequential growth; company maintains strong liquidity with 6.51 current ratio and $1.2M gross profit.
  • Company expects continued growth from CGuard Prime expansion; next-gen delivery system launch planned Q4 2026; analyst price targets range $4-$6.
  • CEO Slosman highlighted successful U.S. market penetration strategy; TCAR-indicated CGuard Prime FDA approval anticipated Q3 2026 amid controlled expansion.
Last Updated: 2026-03-18, 09:16 a/m
Read Full Transcript

Compare NSPR to Peers and Sector

Metrics to compare
NSPR
Peers
Sector
Relationship
P/E Ratio
−1.3x−3.5x−0.4x
PEG Ratio
−2.070.050.00
Price/Book
1.1x3.1x2.6x
Price / LTM Sales
6.9x3.5x3.2x
Upside (Analyst Target)
270.4%46.2%46.7%
Fair Value Upside
Unlock17.6%7.6%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 5.000
(+290.63% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Lake Street Capital Markets
Buy5.00+290.63%-MaintainFeb 24, 2026
Maxim Group
Buy6.00+368.75%-New CoverageFeb 02, 2026
Piper Sandler
Buy4.00+212.50%4.50MaintainMay 12, 2025

Earnings

Latest Release
Mar 18, 2026
EPS / Forecast
-0.14 / -0.19
Revenue / Forecast
3.15M / 2.32M
EPS Revisions
Last 90 days

NSPR Income Statement

People Also Watch

4.250
ABUS
-4.06%
18.0200
ASRT
-0.06%
0.012
ITRMF
-25.16%
2.710
MNKD
-1.09%
4.04
BATL
+0.50%

FAQ

What Is the InspireMD (NSPR) Stock Price Today?

The InspireMD stock price today is 1.280 USD.

What Stock Exchange Does InspireMD Trade On?

InspireMD is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for InspireMD?

The stock symbol for InspireMD is "NSPR."

What Is the InspireMD Market Cap?

As of today, InspireMD market cap is 61.650M USD.

What Is InspireMD's Earnings Per Share (TTM)?

The InspireMD EPS (TTM) is -0.758.

When Is the Next InspireMD Earnings Date?

InspireMD will release its next earnings report on May 12, 2026.

From a Technical Analysis Perspective, Is NSPR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has InspireMD Stock Split?

InspireMD has split 6 times.

How Many Employees Does InspireMD Have?

InspireMD has 127 employees.

What is the current trading status of InspireMD (NSPR)?

As of Apr 24, 2026, InspireMD (NSPR) is trading at a price of 1.280 USD, with a previous close of 1.280 USD. The stock has fluctuated within a day range of 1.250 USD to 1.350 USD, while its 52-week range spans from 1.250 USD to 2.932 USD.

What Is InspireMD (NSPR) Price Target According to Analysts?

The average 12-month price target for InspireMD is 5.000 USD, with a high estimate of 6 USD and a low estimate of 4 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +290.63% Upside potential.

What Is the NSPR After Hours Price?

NSPR's last after hours stock price is 1.340 USD, the stock has decreased by 0.060, or 4.690%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.